ActoBio Therapeutics (former ActoGenix))

ActoBio Therapeutics platform represents a novel class of biopharmaceuticals forging a new frontier in cellular therapeutics. Building on the advantages of protein-based biopharmaceuticals, inlcuding high selectivity and low toxicity, they have the potential to facilitate targeted therapies against a broad range of diseases. A key benefit is these oral biopharmaceuticals are manufactured at a cost that is unprecedented for many biological compounds currently administered by injection.